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Résumé 
Dans la maladie de Crohn, le clinicien ne dispose pas toujours d'études prospectives randomisées ou 
autres preuves solides sur lesquelles appuyer sa décision thérapeutique. Pour pallier ce manque, la 
méthode RAND, qui combine une revue détaillée de la littérature et une synthèse méthodique de 
l'opinion d'experts, a été utilisée pour développer des critères détaillés d'adéquation de traitements pour 
les différentes présentations cliniques de la maladie de Crohn. La présente étude a eu pour but 
d'examiner la faisabilité d'une utilisation rétrospective de ces critères dans une cohorte de patients 
souffrant de maladie de Crohn. 
Les dossiers médicaux des patients ayant consulté leur spécialiste au moins une fois dans les 6 mois 
précédents ont été revus à la recherche des éléments établis par les experts. Pour les dossiers 
contenant tous les éléments nécessaires, l'adéquation des divers traitements a été évaluée. 
Les dossiers médicaux de 260 patients suivis par 22 gastro-entérologues ont été examinés. 116 
patients ont été exclus pour absence de consultation dans les 6 mois précédents. 136 patients (53%) 
représentant 148 consultations ont été retenus. Dans plus de 90% des cas, les éléments .nécessaires à 
l'évaluation de l'adéquation du traitement étaient disponibles, cette proportion variant quelque peu selon 
· la catégorie de la maladie. En appliquant les critères lorsque les éléments nécessaires étaient présents 
dans le dossier médical, 18% des indications aux traitements étaient appropriées, 29% inappropriées et 
pour 38% l'indication était incertaine. Pour 15% des cas, la situation clinique rencontrée n'avait pas été 
explicitement évaluée par les experts. 
Les informations nécessaires à l'évaluation des indications aux divers traitements de la maladie de 
Crohn sont disponibles dans la très grande majorité des dossiers médicaux, permettant ainsi 
l'évaluation de l'adéquation des traitements. Cette étude ouvre la voie à l'utilisation prospective de ces 
critères. 
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Abstract 
Background : Situations where practical therapeutic decisions differ from guidelines in the 
management of patients with Crohn's disease (CD) have been described through opinion surveys. The 
feasibility of actually documenting these situations using an explicit approach has not been examined .. 
Objective : The aim of this study was to evaluate the feasibility of a retrospective application of 
appropriateness criteria to a population of CD patients. 
Methods : Medical records of a cohort of patients diagnosed with CD were systematically reviewed. We 
used appropriateness criteria for treatment of CD that had been developed by the European Panel on 
the Appropriateness of Crohn's disease Therapy (EPACT). First we evaluated the level of precision of 
the elements abstracted from medical records needed in order to be able to apply these criteria. We 
then assessed the appropriateness of treatment for different CD categories. Only participants with at 
least one physician encounter during the last six months were included. 
Results : 260 patient medical records were reviewed on site at 22 gastroenterologists' offices over a 2-
month period in 2005. 116 (44%) patients were excluded because they did not have at least one 
medical visit at their referred gastroenterologist during the last six months. Medical records for eight 
additional patients (3%) were not accessible. One hundred thirty-six (53%) medical records including 
148 encounters were available for analysis. Overall, elements necessary to determine the 
appropriateness of treatment were available in 94% (139/148) of encounters. These elements were 
available in more than 90% of cases for all CD categories except for mild-moderate luminal active CD 
where 66% were avaîlable. Among those with all necessary elements available, 18% of treatments were 
judged as appropriate, 29% inappropriate, 38% uncertain according to the EPACT criteria, and for the 
other 15%, appropriateness had not been rated by the EPACT panel. 
Conclusions : The information necessary to assess the appropriateness of treatment of major type of 
CD was generally bath present and precise in medical records. Therefore, in addition to the intended 
prospective use of these criteria, retrospective evaluation of the appropriateness of CD treatment using 
medical records is also feasible with the EPACT criteria. 
4 
INTRODUCTION 
Although the implementation of practice guidelines for inflammatory bowel disease has been shown to 
reduce practice variation and improve patient quality of life [1], some patients with Crohn's disease (CD) 
still do not receive optimal therapy [2]. Situations where therapeutic decisions differ from practice 
guidelines in the management of CD have been described [3], but there are important conceptual and 
operational obstacles to the actual documentation of such situations and, partly for this reason, their 
actual frequency has not yet been evaluated. 
ln 2004, the European Panel on the Appropriateness of Crohn's disease Therapy (EPACT) developed 
explicit, detailed, and clinically specific criteria for the appropriateness of care, using the RAND/ UCLA 
appropriateness method [4,5]. These criteria are operationalized in 569 clinical scenarios, grouped in 
broad clinical categories. Although the criteria are designed to be used prospectively, we were 
interested in evaluating appropriateness of care at baseline, retrospectively, using medical records. 
Therefore, as a prelude to wider implementation in a large national cohort study currently being 
launched in Switzerland [Swiss National Science Foundation grant no. 3347C0/108792, Swiss IBD 
Cohort Study], and in the perspective of an international (European) application of these criteria, the aim 
of this pilot study was to evaluate the feasibility of using medical records to assess the appropriateness 
ofcare of CD. 
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METHODS 
Participants 
During 2004, we identified ail adults patients with a diagnosis of either CD or ulcerative colitis in the 
canton of Vaud, Western Switzerland, (650'000 inhabitants) by surveying the records of the pathology 
laboratories serving the area, the letters of discharge from the tertiary reference hospital and ail the 
words documents of ail the gastroenterologists practicing in the defined area for the words "Crohn" and 
"ulcerative colitis". A collaboration with the Swiss IBD patient organisation was also set up to stimulate 
patients to participate in the cohort. Written informed consent was obtained from participants for their 
enrolment in a population-based cohort of patients with inflammatory bowel disease. This study focused 
on patients with CD. 
Study design 
A refrospective review of patient records was conducted by one investigator (IG). Participants' medical 
records wère consulted in the practices of participating gastroenterologists (N=22) during a 2-month 
period (April - May 2005) in order to assess the availability of the elements necessary to evaluate the 
appropriateness of care, using the EPACT criteria. Among the 22 gastroenterologists, four were working 
in hospitals and three had a particular interest in IBD. To avoid an inordinate time lag between the 
development of the criteria and the medical decisions being evaluated, we limited our study to patients 
with an encounter with their gastroenterologist within the six months preceding the date of medical 
record review. 
Patient identification and date of last medical encounter were used to determine eligibility. Any face-
to-face visit, phone call or e-mail contact with the gastroenterologist was considered as a medical 
encounter. Laboratory results with no mention of patient contact were not considered as a medical 
encounter. Each medical record was reviewed with a focus on patient history, endoscopies, 
laboratory tests, pathology and radiological reports necessary to apply the EPACT criteria. Current 
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and past treatments were recorded, including duration of treatment and clinical response. Clinical 
response was recorded as complete (prolonged clinical remission with or without endoscopie 
remission); partial (improvement without remission or transitory remission); failure (clinical non-
amelioration or worsening or an adverse event); not assessable (response was not found in the 
medical record). 
If a patient had more than one encounter during this time period, each visit presenting a different event 
of CD (e.g., luminal disease then fistulizing) was reported separately. Thus, for purposes of examining 
appropriateness of care, each event (even if concerning the same patient) corresponded to a separate 
medical decision. 
CD category, as used during the EPACT conference, was established for each participant and before 
assessing the appropriateness of treatment, we determined the level of precision of this information. 
The precision of each CD category was therefore evaluated by documenting criteria included in the 
definitions proposed for broad clinical categories of CD [6-12]. If the medical record reported at least 
one of the criteria from the definitions and included supporting documentation, this element was 
considered as "present and precise". If the medical record mentioned the item, but none of the criteria 
used to define the category were documented, this element was considered as "present but imprecise". 
For example, mention of fistulizing CD in the medical record was judged as present and precise if the 
medical record contained documentation of a digital rectal examination, a fistulography, a computed 
tomography, an MRI or an endoscopie ultrasonography, according to the definition used by the EPACT 
panel and included in the EPACT website [13]. Otherwise it was considered present but imprecise. 
According to these defined criteria, we estimated situations where current treatment options differed 
from the EPACT criteria. These criteria and results are available on the EPACT website (www.epact.ch) 
[13]. 
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Data Analysis 
Data were collected using the ACCESS software, using a double entry system to minimize error. 
Analyses of proportions of appropriate treatment were performed using the ST A TA software 8.0. 
RESULTS 
Sample Characteristics 
A total .of 260 patient's medical records were consulted over a 2-month period. One hundred sixteen 
patients' medical records (44%) were excluded because they did not have at least one medical 
encounter with the gastroenterologist during the preceding six months. Eight (3%) medical records were 
not accessible. One hundred thirty-six medical records including 148 encounters were available for 
analysis. Thirty-five percent (47/136) concerned patients seen by staff at the University hospital. The 
majority of patients were female (58%), and the mean age was 43 years +/-14 (SD, range 18-100). Most 
(91 %) were diagnosed with CD after 1980. The most frequent location of CD at diagnosis was 
ileocolonic (44%). The most frequent category encountered was lu minai CD (81 %) (Table 1 ). Of the 569 
possible detailed scenarios in the EPACT criteria, only 35 were actually encountered in this study. Two-
thirds of patients were in remission at their last visit, and remission had been medically-induced for 
more than 80% of them (Table 1). 
Precision of information 
CD category was established for each participant and the precision of this information assessed. For the 
initial sorting of case into broad clinical categories, information was present and precise for ail cases of 
mild-moderate and severe active luminal CD (19/19), maintenance of medically-induced remission CD 
(74174) and maintenance of surgically-induced remission CD (15/15). Information was present but 
imprecise for.2 of the 12 patients with steroid-dependent CD, both cases of steroid-refractory CD (2/2), 
2 of the 15 patients with fistulizing CD, and 5 of the 11 patients with fibrostenotic CD. 
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Proportion of encounters with ail elements necessary to determine appropriate treatment 
Among the 148 encounters, necessary elements ta determine treatment appropriateness, based on the 
EPACT criteria, were available in 139 encounters (94%) (Table 2). For ail CD categories, except the 
mild-moderate active luminal CD, the proportion of encounters with all elements was over 90%. 
Concerning the mild-moderate active luminal CD category, necessary elements were missing for six 
encounters (34%), involving 5 gastroenterologist practices; CD locations were not defined in three of 
them, and prior prednisone treatment responses were not available for the other three. 
Appropriateness of treatment 
After evaluating the level of precision of the elements abstracted from medical records, we estimated 
the appropriateness of treatment for the different categories of CD (Table 3). 
Overall, we found that 18% of treatment were appropriate, 29% inappropriate, 38% uncertain while 15% 
of treatment encountered had not been rated during the EPACT panel. The main reasons for the latter 
were that the panel had considered them as invalid indications, e.g. prescription of antibiotics in prior 
antibiotics therapy failure, or because they were simply not rated by the panel. A considerable number 
(49 cases) of treatments of uncertain indication were found in maintenance of medically-induced 
remission CD. Most of them were due ta azathoprine therapy prescribed in low-risk patient with 
medically-induced remission CD, and wait and see attitude in maintenance of medically-induced 
remission (8 cases). lnappropriate therapies were found in low-risk patient with medically-induced 
remission CD. 
When considering appropriateness by treatment (Table 4), azathioprine was the most frequent (56/153) 
treatment encountered. More than 40% (20/45) of therapeutic decisions considered as inappropriate by 
applying the EPACT criteria were in relation ta oral mesalazine. 
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DISCUSSION 
For more than 94% of CD patients foilowed in gastroenterology practices, elements necessary to judge 
the appropriateness of care could be identified retrospectively in the medical records, thus confirming 
the feasibility of this approach to evaluating quality of care for these patients. 
This study also demonstrated that according to the EPACT criteria, ail elements were not always crucial 
to assess the appropriateness of CD treatment. lndeed, even though ail elements were not accessible, 
appropriateness evaluation was in tact feasible for ail but 6% of prescriptions. On the other hand, this 
study highlights the fact that some elements are indispensable for applying these criteria. lndeed, for 
luminal active CD, the current location of the disease (ileocolonic or colonie) may be missing in medical 
records since endoscopies are not systematically performed in previously known CD patients who 
present an active CD. Thus, initial location (i.e., location of CD at diagnosis) may be used for the current 
location if evidence for another location is not present. 
ln addition to the conclusion that retrospective examination of patient's records can be used to abstract 
the information required to assess the appropriateness of care in CD, this study also demonstrated the 
feasibility of quantifying the frequency of situations where therapeutic decisions differ from practice 
guideline in CD. 
According to the EPACT criteria, the majority of treatment decisions encountered in this study were 
considered as uncertain or inappropriate. The most frequent inappropriate decisions were for oral 
mesalazine in maintenance of medically-induced remission CD in patient with low frequency of relapse, 
azathioprine and budesonide in mild-moderate luminal active CD or fibrostenotic CD, and methotrexate 
in mild-moderate luminal active CD. 
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Oral mesalazine in medically-induced remission in patients with low frequency of relapse represent 40% 
of the overall inappropriate treatment. The EPACT panel (2004) considered that in low frequency 
relapsers, smoking cessation was the only clearly appropriate intervention. The common use of 5-ASA 
for maintenance of remission in CD has been based on the results of earlier studies showing that 
mesalazine reduces the risk of clinical disease relapse in Crohn's disease [14, 15]. The European 
Consensus Conference, held in 2004, states that if remission has been achieved medically after the first 
presentation, maintenance with mesalazine is a treatment option, although they indicated that there is 
no consistent evidence for its efficacy [16]. More recently, Akobeng et al., in 2005, found no evidence to 
suggest that 5-ASA preparations are superior to placebo for the maintenance of medically-induced 
remission in patients with Crohn's disease [17]. Thus, if mesalazine were to be considered as an 
appropriate treatment option, the overall proportion of inappropriate treatment in our study would be 
only 16%. 
Uncertain treatments were mainly found in maintenance of medically-induced remission CD (49/79). 
Among those 49 uncertain cases, the majority concern patients with low frequency of relapse (..:;; 2 / 
year) and treated by azathioprine (29 cases). This rather high number of uncertain decisions highlights 
the need of continuing effort for further refining the EPACT criteria, especially concerning indications 
dassified as "uncertain", as they may represent a considerable proportion of therapies prescribed. 
Of the 260 eligible patients, almost half were excluded because they did not have a clinical encounter in 
the last 6 months. This could be interpreted in different ways. lt might mean that those patients are 
treated sufficiently well (appropriately) that they are stable and doing well and don't require attention. 
These patients may also have visited their GP, a gastroenterologist in another area, or favoured 
complementary medicine approaches. The large proportion of excluded patients does not, however, 
detract from the overall finding concerning the feasibility of a retrospective approach tà the assessment 
of cjuality of care in the case of CD. 
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A further limitation of our study is that the doses of drugs were not included in our evaluation of 
appropriateness. Taking account of the drug dose would probably change the rate of inappropriateness. 
However, drug dose is subject to too many factors which are difficult to estimate, including intolerance 
and side effects. Moreover, patient's weight was not systematically indicated in the medical records so 
that determining the dose prescribed per kilogram would have been impractical, if not impossible. 
· Therefore, we assumed that the dose prescribed by the gastroenterologists was the appropriate dose 
for the patient and we did not include this criterion into the appropriateness evaluation. 
Among the strengths of this study is the detailed precision of the criteria used to assess 
appropriateness. The fact that only 35 of the possible 569 detailed scenarios were actually encountered 
in our study -- even considering the small sample of patients -- may suggest that the EPACT criteria are 
too detailed. On the other hand, this study demonstrated that a non-negligible proportion (15%) of 
current treatments were not rated by the EPACT panel, painting to a lack of completeness of those 
criteria. This underscores the need to periodically revisit and update criteria and, through an iterative 
process, align and adjust theoretical criteria with actual data on prevalence of clinical situations. 
Previous medical record studies have used the RAND-based evaluation of appropriateness of care with 
divergent results. While some studies found medical records to be of limited use in assessing the 
appropriate management of care [18, 19], other studies succeed in determining a significant proportion of 
appropriateness of care [20-23]. This underscores the fact that the feasibility of using the medical 
records for evaluating the appropriateness of care may not be generalizable to other settings and other 
disease entities or procedures and need to be validated for each setting. 
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What are the implications of this study? First, as pilot study, preluding the implementation of the Swiss 
IBD cohort study [Swiss National Science Foundation grant no. 3347C0/108792, Swiss IBD Cohort 
Study - SIBDCS], this study confirms that it will be possible ta obtain a baseline notion of the 
appropriateness of care for patients at enrollment in the cohort. On the other hand, the aim of the study 
was not ta evaluate the validity of the EPACT criteria, e.g., ta judge the validity of inappropriateness of 
oral mesalazine. T o undertake such an endeavour, it would clearly be preferable ta collect information 
and apply the criteria prospectively as foreseen by the EPACT panel itself and in the SIBDCS. 
ln conclusion, this study demonstrated the feasibility ta use retrospectively RAND panel based criteria 
for the assessment of appropriateness of care in Crohn's disease. This study paves the way for the use 
of these criteria in the evaluation and improvement of care for CD in large cohorts of patients. · 
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Table 1. Type and frequency distribution of CD, according to the disease category used for the 
EPACT expert panel (N=136) (The definitions used are available at the website www.epact.ch) 
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Type of CD N (%) 
Luminal 111 (81.6) 
Fistulizing 15 (11.0) 
Simple fistula 4 (26.7) 
Complex fistula 11 (73.3) 
Fibrostenotic 11 (8.1) 
<?cm 4 (36.3) 
>?cm 6 (54.5) 
Length not mentioned 1 (9.0) 
Small bowel only 9 (81.8) 
Colonie only 1 (9.0) 
Anastomotic 1 (9.0) 
Gastroduodenal 5 (3.7) 
Stenosis 4 (80.0) 
Non stenosis 1 (20.0) 
Extraintestinal 22 (16.2) 
Active 19 (14.0) 
Mild-moderate 18 (94.7) 
Severe 1 (5.3) 
Remission 89 (65.4) 
Medically induced 74 (83.1) 
Low frequency of relapse 67 (90.5) (:::; 2 / year) 
High frequency of relapse 6(8.1) (> 2 / year) 
Not mentioned 1 (1.3) 
Surgically induced 15(16.8) 
Low risk of recurrence 3 (20.0) 
High risk of recurrence 12 (80.0) 
Steroid-dependant 12 (8.8) 
Steroid-refractory 2 (1.5) 
Not mentioned 14 (10.3) 
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Table 2. Proportion of encounters with ail elements necessary to determine appropriate 
treatment 
CD category 
Mild-moderate active luminal CD 
Severe active luminal CD 
Steroid-dependent CD 
Steroid-refractory CD 
Fistulizing CD 
Fibrostenotic CD 
Maintenance of medically-induced remission 
CD 
Maintenance of surgically-induced remission 
CD 
Total· 
Encounters with ail elements/Total 
number of encounters (%) 
12/18 (66) 
1/1 (100) 
12/12 (100) 
2/2 (100) 
14/15 (93) 
11/11 (100) 
73174 (98) 
14/15 (93) 
139/148 (94) 
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Table 3. Appropriateness of treatment (n=number of treatment) 
CD category n A u NR 
Mild-moderate 16 3 2 10 Active Luminal 
Steroid-dependent 8 5 2 
Ste roi d-refra cto ry 5 3 
Fistulizing 19 4 3 12 
Fibrostenotic 14 3 9 2 
Maintenance of 
medically-induced 79 2 49 26 2 
remission 
Maintenance of 
surgically-induced 12 9 2 
remission 
Total 153 (100%) 27 (18%) 58 (38%) 45 (29%) 23 (15%) 
[A] Appropriate; [U] Uncertain; [I] lnappropriate; [NR] Not rated 
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Table 4. Appropriateness considered by treatment (n=numberof treatment)' 
THERAPY n A 
Azathioprine 56 11 
Budesonide 8 
Antibiotics (ciproxine or 6 
metronidazole) 
Dilatation 
lnfliximab 11 3 
Mercaptopurine 4 
Methotrexate 21 4 
Oral mesalazine 26 2 
Prednisone* 8 3 
Resection 
Stricturoplasty 
Sulfasalazine 
Wait & see . 9 
Total 153 (100%) 27 (18%) 
[A] Appropriate; [U] Uncertain; [I] lnappropriate; [NR] Not rated; 
*12 patients with steroid-dependent CD not included 
u 
29 8 
7 
6 2 
2 
10 5 
2 20 
2 
9 
58 (38%) 45 (29%) 
NR 
8 
1 
5 
2 
2 
3 
23 (15%) 
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